PT2501704E - Compostos de espiropiperidina como antagonistas do receptor orl-1 - Google Patents

Compostos de espiropiperidina como antagonistas do receptor orl-1

Info

Publication number
PT2501704E
PT2501704E PT107824864T PT10782486T PT2501704E PT 2501704 E PT2501704 E PT 2501704E PT 107824864 T PT107824864 T PT 107824864T PT 10782486 T PT10782486 T PT 10782486T PT 2501704 E PT2501704 E PT 2501704E
Authority
PT
Portugal
Prior art keywords
receptor
antagagonisten
oral
treatment
compounds
Prior art date
Application number
PT107824864T
Other languages
English (en)
Portuguese (pt)
Inventor
Nuria Diaz Buezo
Maria Angeles Martinez-Grau
Alma Maria Jimenez-Aguado
Celia Lafuente Blanco
Miguel Angel Toledo Escribano
Ana Belen Benito Collado
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT2501704E publication Critical patent/PT2501704E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT107824864T 2009-11-16 2010-11-12 Compostos de espiropiperidina como antagonistas do receptor orl-1 PT2501704E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382245 2009-11-16
US29862810P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
PT2501704E true PT2501704E (pt) 2013-12-05

Family

ID=41800752

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107824864T PT2501704E (pt) 2009-11-16 2010-11-12 Compostos de espiropiperidina como antagonistas do receptor orl-1

Country Status (18)

Country Link
US (1) US20120214784A1 (enExample)
EP (1) EP2501704B1 (enExample)
JP (1) JP5723381B2 (enExample)
KR (1) KR101368130B1 (enExample)
CN (1) CN102666550B (enExample)
AU (1) AU2010319400B2 (enExample)
BR (1) BR112012011710A2 (enExample)
CA (1) CA2781041C (enExample)
DK (1) DK2501704T3 (enExample)
EA (1) EA020391B1 (enExample)
ES (1) ES2436241T3 (enExample)
HR (1) HRP20130969T1 (enExample)
MX (1) MX2012005690A (enExample)
PL (1) PL2501704T3 (enExample)
PT (1) PT2501704E (enExample)
RS (1) RS53017B (enExample)
SI (1) SI2501704T1 (enExample)
WO (1) WO2011060217A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104193761B (zh) 2009-12-04 2017-10-17 桑诺维恩药品公司 多环化合物及其使用方法
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之orl-1受體拮抗劑
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
SG10202100724UA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
EP3497101B1 (de) 2016-08-10 2020-12-30 Bayer CropScience Aktiengesellschaft Substituierte 2-heterocyclyl-imidazolyl-carboxamide als schädlingsbekämpfungsmittel
EP3582815A1 (en) 2017-02-16 2019-12-25 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
LT3589638T (lt) 2017-03-02 2021-06-10 Eli Lilly And Company Junginiai, naudingi ror-gama-t slopinimui
DK3589637T3 (da) * 2017-03-02 2021-06-14 Lilly Co Eli Forbindelser, der er anvendelige til inhibering af ROR-GAMMA-T
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
SG11202007823PA (en) 2018-02-16 2020-09-29 Sunovion Pharmaceuticals Inc Salts, crystal forms, and production methods thereof
LT3897833T (lt) 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
EP3766879A1 (en) 2019-07-19 2021-01-20 Basf Se Pesticidal pyrazole derivatives
KR20230003503A (ko) 2020-04-14 2023-01-06 선오비온 파마슈티컬스 인코포레이티드 신경학적 및 정신의학적 장애의 치료를 위한 (S)-(4,5-디히드로-7H-티에노[2,3-c]피란-7-일)-N-메틸메탄아민
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
CN119343353A (zh) * 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003095427A1 (en) 2002-05-10 2003-11-20 Taisho Pharmaceutical Co.,Ltd. Spiro-ring compound
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
WO2005092858A2 (en) * 2004-03-29 2005-10-06 Pfizer Japan Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2522669B1 (en) * 2005-06-02 2016-12-28 Janssen Pharmaceutica NV 3-Spirocyclic indolyl derivatives useful as ORL-1 receptor modulators

Also Published As

Publication number Publication date
WO2011060217A1 (en) 2011-05-19
JP5723381B2 (ja) 2015-05-27
CN102666550B (zh) 2015-07-15
EA201290355A1 (ru) 2012-10-30
EP2501704A1 (en) 2012-09-26
BR112012011710A2 (pt) 2016-03-01
US20120214784A1 (en) 2012-08-23
JP2013510870A (ja) 2013-03-28
MX2012005690A (es) 2012-06-13
CA2781041C (en) 2015-01-06
KR101368130B1 (ko) 2014-02-27
EP2501704B1 (en) 2013-09-18
AU2010319400B2 (en) 2013-12-19
EA020391B1 (ru) 2014-10-30
ES2436241T3 (es) 2013-12-27
DK2501704T3 (da) 2013-10-14
CN102666550A (zh) 2012-09-12
CA2781041A1 (en) 2011-05-19
SI2501704T1 (sl) 2013-11-29
PL2501704T3 (pl) 2014-02-28
RS53017B (sr) 2014-04-30
HRP20130969T1 (hr) 2013-11-22
KR20120082927A (ko) 2012-07-24
AU2010319400A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
PH12012500969A1 (en) Spiropiperidine compounds as orl-1 receptor antagonists
EA201290355A1 (ru) Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
UA102857C2 (en) Quinuclidine carbonate derivatives and use thereof
UA107334C2 (ru) Производные аминоэфиров алкалоидов и их лекарственные композиции
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
PH12015501289A1 (en) Novel benzimidazole derivatives as ep4 antagonists
MX352881B (es) Metodos y compuestos utiles en la sintesis de antagonistas del receptor de orexina 2.
PH12012500572A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011121418A9 (en) 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists
IN2012DN02735A (enExample)
IN2012DN00754A (enExample)
MX2010009955A (es) Derivados de ciclohexano espirociclicos sustituidos.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MY172809A (en) Spirothienopyran-piperidine derivatives as orl-1 receptor antagonists for their use in the treatment of alcohol dependence and abuse
PH12012502300A1 (en) Nicotinic receptor non-competitive antagonists
TN2012000207A1 (en) Spiropiperidine compounds as orl-1 receptor antagonists
MX2011008458A (es) Metodos para preparar agonistas y antagonistas del receptor s1p.
WO2009108635A3 (en) Novel compositions for treatment of diseases related to activated lymphocytes
CY1114664T1 (el) Ενωσεις σπιροπιπεριδινης ως ανταγωνιστες υποδοχεα orl-1
CL2012001262A1 (es) Compuestos derivados de espiropiperidina; composicion farmaceutica; y uso como antagonistas del receptor orl-1 en el tratamiento de la depresion, migraña, obesidad.
TN2011000063A1 (en) Quinuclidine carbonate derivatives and medicinal composition thereof
UA96037C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства антиалкогольного действия
UA96048C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства фригопротекторного действия
PH12013501453A1 (en) Nicotinic receptor non-competitive antagonists